Acuta Capital Partners as of June 30, 2022
Portfolio Holdings for Acuta Capital Partners
Acuta Capital Partners holds 43 positions in its portfolio as reported in the June 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Apellis Pharmaceuticals (APLS) | 14.0 | $25M | 554k | 45.22 | |
| Aadi Bioscience (AADI) | 10.5 | $19M | 1.5M | 12.32 | |
| Vistagen Therapeutics Com New | 5.6 | $10M | 11M | 0.88 | |
| Kura Oncology (KURA) | 5.5 | $9.8M | 537k | 18.33 | |
| Bcls Acquisition Corp- Cl A Com Cl A | 4.7 | $8.3M | 843k | 9.90 | |
| Xenon Pharmaceuticals (XENE) | 4.6 | $8.3M | 273k | 30.42 | |
| Bellus Health Com New | 4.2 | $7.5M | 816k | 9.24 | |
| Celldex Therapeutics Com New (CLDX) | 4.0 | $7.2M | 267k | 26.96 | |
| Relmada Therapeutics (RLMD) | 3.7 | $6.7M | 353k | 18.99 | |
| Mirati Therapeutics | 3.5 | $6.3M | 95k | 67.13 | |
| Jiya Acquisition Corp -cl A Com Cl A | 3.1 | $5.6M | 563k | 9.87 | |
| Iveric Bio | 3.0 | $5.4M | 564k | 9.62 | |
| Roche Holding | 3.0 | $5.3M | 16k | 333.62 | |
| Arcus Biosciences Incorporated (RCUS) | 2.4 | $4.2M | 168k | 25.34 | |
| Syndax Pharmaceuticals (SNDX) | 2.2 | $3.9M | 205k | 19.24 | |
| Health Sciences Acquisitions Ord Shs | 2.2 | $3.9M | 393k | 9.96 | |
| Merus N V (MRUS) | 1.9 | $3.5M | 154k | 22.64 | |
| Precision Biosciences Ord | 1.8 | $3.3M | 2.1M | 1.60 | |
| United Therapeutics Corporation (UTHR) | 1.7 | $3.1M | 13k | 235.62 | |
| Horizon Therapeutics SHS | 1.6 | $2.9M | 36k | 79.75 | |
| Milestone Pharmaceuticals (MIST) | 1.6 | $2.8M | 457k | 6.15 | |
| Miragen Therapeutics (VRDN) | 1.5 | $2.7M | 234k | 11.57 | |
| Aclaris Therapeutics (ACRS) | 1.5 | $2.7M | 193k | 13.96 | |
| Gh Research Ordinary Shares (GHRS) | 1.4 | $2.4M | 243k | 9.98 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 1.3 | $2.4M | 303k | 7.87 | |
| Arrowhead Pharmaceuticals (ARWR) | 1.2 | $2.2M | 62k | 35.20 | |
| Pmv Pharmaceuticals (PMVP) | 1.2 | $2.2M | 153k | 14.25 | |
| Rezolute Com New (RZLT) | 1.2 | $2.1M | 645k | 3.23 | |
| Iovance Biotherapeutics (IOVA) | 0.9 | $1.7M | 154k | 11.04 | |
| Pyxis Oncology Common Stock (PYXS) | 0.9 | $1.5M | 645k | 2.38 | |
| Ventyx Biosciences (VTYX) | 0.8 | $1.5M | 122k | 12.23 | |
| Enanta Pharmaceuticals (ENTA) | 0.7 | $1.3M | 28k | 47.27 | |
| Iteos Therapeutics (ITOS) | 0.7 | $1.3M | 62k | 20.60 | |
| ACADIA Pharmaceuticals (ACAD) | 0.6 | $1.0M | 72k | 14.08 | |
| Fulcrum Therapeutics (FULC) | 0.5 | $980k | 200k | 4.90 | |
| Ac Immune Sa Call Option | 0.2 | $354k | 100k | 3.54 | |
| Athira Pharma Call Option | 0.2 | $340k | 100k | 3.40 | |
| Gossamer Bio (GOSS) | 0.1 | $268k | 32k | 8.38 | |
| Verastem | 0.1 | $232k | 200k | 1.16 | |
| Springworks Therapeutics (SWTX) | 0.1 | $123k | 5.0k | 24.60 | |
| Trevi Therapeutics (TRVI) | 0.1 | $98k | 35k | 2.80 | |
| Ocular Therapeutix (OCUL) | 0.0 | $53k | 13k | 4.02 | |
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $25k | 91k | 0.28 |
